Dupilumab Shows Positive Results in Skin of Colour AD Trial

Regeneron and Sanofi’s Phase IV DISCOVER trial of Dupixent (dupilumab) in adolescents and adults with moderate-to-severe atopic dermatitis (AD) and skin of colour showed promising results. Presented at the 2025 Revolutionizing Atopic Dermatitis Conference, the study involved 120 patients treated biweekly for 24 weeks.

At week 24, 76% achieved EASI-75 (≥75% improvement in disease severity), with some seeing benefits by week two. Additionally, 53% experienced reduced itch and post-inflammatory hyperpigmentation. The safety profile was consistent with existing data.

Participants (≥12 years) received weight-based monotherapy. The trial included Fitzpatrick skin types IV-VI, which often experience more severe AD. Dupixent, developed using Regeneron’s VelocImmune technology, targets IL-4 and IL-13 pathways without immune suppression.

Regeneron and Sanofi also announced that the Phase III AERIFY-1 trial of itepekimab in COPD met its primary endpoint.

18-06-2025